Single dose pharmacokinetics and bioavailability of BLX-1002 - A novel anti dibetic compound in rats

被引：0
|
作者：
Nag, A [1 ]
Dey, D [1 ]
Gutala, S [1 ]
Neogi, P [1 ]
Pandey, B [1 ]
Nag, B [1 ]
机构：
[1] Bexel Pharmaceut Inc, Union, CA 94587 USA
来源：
FASEB JOURNAL | 2004年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：A605 / A605
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics and bioavailability of BLX-1002 - A single amino acid conjugated anti diabetic compound in dogs
    Nag, A
    Neogi, P
    Dey, D
    Pandey, B
    Gutala, S
    Nag, B
    FASEB JOURNAL, 2004, 18 (04): : A605 - A606
  • [2] 90-Day toxicological evaluation of BLX-1002, a novel anti-diabetic compound in rats
    Nag, A
    Bhatnagar, U
    Sen, AP
    Neogi, P
    Dey, D
    Nag, B
    FASEB JOURNAL, 2005, 19 (04): : A828 - A828
  • [3] Pharmacokinetics studies of BLX-1002 in Sprague Dawley rats and beagle dogs
    Gutala, S
    Nag, A
    Gupta, A
    Sreenivasan, P
    Chang, D
    Neogi, P
    Nag, B
    Dey, D
    DIABETES, 2004, 53 : A483 - A483
  • [4] Identification and characterization of the major metabolite of BLX-1002, a novel orally active anti-diabetic compound
    Gutala, S
    Nag, A
    Balse, P
    Neogi, P
    Nag, B
    Dey, D
    FASEB JOURNAL, 2004, 18 (04): : A605 - A605
  • [5] In vitro and In vivo activities of the major metabolite of a novel anti-diabetic compound BLX-1002
    Gutala, S
    Gupta, A
    Pandey, B
    Nag, A
    Nag, B
    Dey, D
    FASEB JOURNAL, 2004, 18 (04): : A608 - A609
  • [6] Toxicological evaluation of an anti hyperglycemic compound BLX-1002 approaching to clinical trials
    Nag, A
    Moon, H
    Gutala, S
    Neogi, P
    Agarwal, SK
    Dey, D
    Nag, B
    DIABETES, 2004, 53 : A139 - A139
  • [7] Amino acid conjugated, orally active, novel anti-diabetic compound BLX-1002 has no affinity to PPARγ
    Dey, D
    Pandey, B
    Nag, A
    Neogi, P
    Nag, B
    DIABETES, 2004, 53 : A483 - A483
  • [8] Anti-inflammatory Properties of Novel Antidiabetic Compound BLX-1002, Which Lowers Body Weight Gain in Obese Mice
    Dey, Deben
    Pandey, Bindu
    Anumula, Madhavi
    Nag, Abhijeet
    Neogi, Partha
    Nag, Bishwajit
    INFLAMMATION RESEARCH, 2005, 54 : S106 - S106
  • [9] Mechanism of action studies with novel thiazolidinedione BLX-1002 with no PPARγ affinity
    Dey, D
    Anumula, M
    Pandey, B
    Nag, A
    Neogi, P
    Nag, B
    DIABETOLOGIA, 2005, 48 : A44 - A44
  • [10] Novel anti-diabetic compound BLX-1002 with no affinity to PPARα, γ and δ, lowers serum triglyceride levels and systolic blood pressure in fructose fed rats
    Dey, D
    Chovatia, M
    Nag, A
    Pandey, B
    Nag, B
    DIABETOLOGIA, 2004, 47 : A256 - A257
12345